 |
|
|
| |
Glecaprevir/Pibrentasvir (G/P) and Ezetimibe for 8 Days Should Be the New Standard of Care With 100% Efficacy to Prevent Chronic HCV Infection in Non-liver Solid Organ Transplant (Sot) Recipients of HCV-VIREMIC Grafts
|
| |
| |
AASLD Nov 4-8 2022
Bashar A. Aqel, MD; Surakit Pungpapong,MD ; Adyr Moss,MD²; Kristen Ryland; Michael D Leise,MD; Rolland Dickson, MD.
Gastroenterology & Hepatology, Mayo Clinic Arizona, ²Transplant Surgery, Mayo Clinic Arizona
Transplantation, Mayo Clinic, Mayo Clinic Florida, Gastroenterology and Hepatology, Mayo Clinic Rochester
|
| |
|
|
|
|
|
